



**The Jackson
Laboratory**

*Leading the search
for tomorrow's cures*

FORUM FOR DISCOVERY

July 16, 2026 | Bar Harbor, ME

BREAKTHROUGH SCIENCE.

REAL-WORLD IMPACT.

For nearly a century, research-driven discoveries at The Jackson Laboratory have transformed our approach to cancer, Alzheimer's disease, rare conditions, and more. Today, you'll see how JAX is reimagining the future of human health — and leading the way. **Thank you** for joining us on the journey.

- 2:00 p.m. **INTRODUCTION**
CHRISTINE LIN EGLI
Vice President of Advancement
- 2:05 p.m. **PRESIDENT'S WELCOME**
LON CARDON, Ph.D., FMedSci
President & Chief Executive Officer
- 2:25 p.m. **SESSION I FIRESIDE CHAT: BRINGING
WORLD-CLASS CANCER CARE CLOSER TO HOME**
Moderator: Christine Lin Egli
JENS RUETER, M.D.
*Chief Medical Officer, JAX
Medical Director, Maine Cancer Genomics Initiative*
PHILIP BROOKS, M.D.
Physician, Eastern Maine Medical Center Cancer Care
CORA FAHY
Patient Advocate & Cancer Survivor
Q&A
- 3:00 p.m. **BREAK**
- 3:15 p.m. **REFLECTIONS ON A SUMMER AT JAX**
ANELLA BOLSTER, WHEATON COLLEGE
2026 Summer Student Program Participant
- 3:20 p.m. **SESSION II THE NEW ERA OF BIOMEDICAL RESEARCH**
MARY DICKINSON, Ph.D.
Executive Vice President & Chief Scientific Officer
DANIEL PAULL, Ph.D.
*Scientific Director, JAX-NYSCF
Vice President, Discovery & Platform Development*
MATT MAHONEY, Ph.D.
Principal Computational Scientist
Q&A
- 3:58 p.m. **CLOSING REMARKS**
CHRISTINE LIN EGLI
- 4:00 p.m. **IN-PERSON RECEPTION & POSTER FAIR**
ROSCOE'S CAFE
- 5:00 p.m. **RECEPTION CONCLUDES**



LON CARDON, Ph.D., FMedSci

PRESIDENT AND CHIEF EXECUTIVE OFFICER

Cardon, a globally renowned human geneticist, became president and CEO of The Jackson Laboratory in November 2021. Since then, he has led a bold strategic vision that builds on JAX's nearly 100-year expertise in mouse models and genetics. Under his leadership, JAX has expanded into cellular modeling and data science to establish a first-of-its-kind discovery platform designed to accelerate cures and transform human health.

Prior to JAX, he served as the chief scientific officer and chief scientific strategy officer at BioMarin Pharmaceutical Inc., a rare disease biotechnology company. Before BioMarin, he served as senior vice president and head of genetics, quantitative sciences and alternative discovery/development at GlaxoSmithKline plc. In addition to division management responsibilities, he was chair of GSK's Discovery Investment Board, overseeing research funding across all therapeutic areas.

Cardon spent the first half of his career as a senior academic. From 1998 to 2006 he was a faculty member at the University of Oxford, initially as head of bioinformatics and statistical genetics at the Wellcome Trust Centre for Human Genetics, and later as a Wellcome Trust principal fellow and professor of bioinformatics. From 2006 to 2008, he was a professor of biostatistics at the University of Washington and co-chair of the Herbold Bioinformatics Program at the Fred Hutchinson Cancer Research Center in Seattle. Cardon's academic groups discovered dozens of genes for common and rare diseases and his industry groups advanced broad portfolios in large pharmaceutical and mid-size biotechnology companies, from exploratory research to phase I-III clinical trials. He has authored more than 225 scientific publications and 15 books and chapters on genetics methodology, applications, and discoveries in rare and common diseases. He is an elected fellow of the United Kingdom's Academy of Medical Sciences and the American Association for the Advancement of Science.



PHILIP BROOKS, M.D.

PHYSICIAN, EASTERN MAINE MEDICAL CENTER CANCER

Brooks is a staff physician in oncology/hematology at Cancer Care of Maine, seeing patients at hospitals in Bar Harbor, Ellsworth, and Blue Hill. A graduate of the University of Pennsylvania School of Medicine, he completed his hematology-oncology fellowship at Dartmouth-Hitchcock. Brooks joined Eastern Maine Medical Center in 1980, serving as tumor clinic director and section head. He helped found Cancer Care of Maine and expand regional oncology programs. Internationally, he established an oncology clinic in Beijing and directed medical operations at United Family Hospitals.



MARY DICKINSON, Ph.D.

EXECUTIVE VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER

Dickinson is the executive vice president and chief scientific officer at The Jackson Laboratory. She leads JAX's research enterprise, overseeing scientific strategy and operations to build on JAX's unique strengths in genetics and genomics. She is responsible for recruiting faculty and overseeing new initiatives and collaborations.

Prior to JAX, Dickinson served as the senior vice president and dean of research at Baylor College of Medicine. Dickinson earned her doctorate from Columbia University. She has authored more than 150 manuscripts, holds several patents, and has received numerous awards. She was elected a fellow of the American Institute of Medical and Biological Engineering. In 2023, she was elected to the Society for Developmental Biology Academy and received the Orbus Pictus award from the International Society for Transgenic Technology. Most recently, Dickinson was recognized with the lifetime honor of being elected a fellow of the American Association for the Advancement of Science.



CORA FAHY

PATIENT ADVOCATE AND CANCER SURVIVOR

Fahy is an 11-year breast cancer survivor who has spent much of her survivorship journey supporting and advocating for others affected by cancer. Since her diagnosis in 2015, she has shared her experience in hopes of helping others feel less alone while navigating treatment, recovery and life after cancer.

She has been involved in advocacy work through the Maine Cancer Genomics Initiative, the Dempsey Center for Quality Cancer Care, the Beth C. Wright Cancer Resource Center, and Cancer Nation, including mentorship and advocacy efforts in Washington, D.C. She has also participated in fundraising, peer support, awareness campaigns, and social media outreach focused on early detection, survivorship, and patient support.

Fahy is a strong believer in the power of education. She encourages people, particularly within the breast cancer community, to learn about their diagnosis, ask questions, and advocate for themselves, believing that knowledge helps patients make informed decisions about their care. Through transparency, humor, and compassion, she hopes to help others facing cancer feel supported, informed, and a little less alone.



CHRISTINE LIN EGLI

VICE PRESIDENT OF ADVANCEMENT

Lin Egli joined The Jackson Laboratory in 2025, bringing over two decades of experience in non-profit leadership and philanthropy. She most recently served as chief advancement officer and strategic advisor to the president and CEO at The New York Stem Cell Foundation. As chief advancement officer and an executive team member of NYSCF since 2013, Christine partnered with internal and external leaders to expand NYSCF's scientific programs and research facilities. She joined NYSCF from the international fundraising consulting firm CCS, where she served as a vice president.

A violinist of over 35 years, Lin Egli is a lifelong champion of the performing arts. She previously worked at the Yale School of Music and currently serves on the Boards of the Harvard-Radcliffe Orchestra Foundation and the Chelsea Music Festival in New York City, reflecting her continued commitment to artistic excellence and community engagement.

Lin Egli holds an AB in psychology from Harvard College and an MBA from the Yale School of Management.



MATT MAHONEY, Ph.D.

PRINCIPAL COMPUTATIONAL SCIENTIST

Mahoney is a mathematician and systems biologist interested in the genetics of disease, especially so-called complex diseases for which no single gene mutation is responsible. He received his Ph.D. in mathematics from Dartmouth College in 2009 and subsequently completed two post-doctoral fellowships, one in genetics and another in neuroscience at Dartmouth and the University of Vermont (UVM), respectively. In 2016, Mahoney was appointed as assistant professor in the department of neurological sciences at UVM. In 2020, firm in the conviction that genetic diversity is the essential perspective through which to study human disease, he moved to JAX as a senior computational scientist to take part in JAX's growing ambitions for institution-scale science. His work combines physics, mathematics, modern artificial intelligence and machine learning to search for the fundamental simplicity in biology that emerges from its astounding complexity. He is currently leading the JAX CARDIOVERSE project to build better tools for predicting drug side effects that harm the heart, a leading cause of clinical trial failure.



DANIEL PAULL, Ph.D.

SCIENTIFIC DIRECTOR, JAX-NYSCF
AND VICE PRESIDENT, DISCOVERY
AND PLATFORM DEVELOPMENT

Paull joined The Jackson Laboratory in 2025 following its acquisition of the New York Stem Cell Foundation, where he leads the Global Stem Cell Array®, an automated platform for large-scale stem cell production and disease modeling. His work integrates biology, engineering, and AI to improve consistency and scalability in iPSC research. Paull earned his Ph.D. from University College London and completed postdoctoral training at NYSCF, where he helped develop advanced stem cell technologies, including automation systems and mitochondrial replacement techniques aimed at preventing inherited mitochondrial diseases.



JENS RUETER, M.D.

CHIEF MEDICAL OFFICER, MEDICAL DIRECTOR,
MAINE CANCER GENOMICS INITIATIVE

Rueter joined JAX in August 2016 to found and lead the Maine Cancer Genomics Initiative (MCGI), a statewide program that delivers complex genomic tumor testing to cancer patients across Maine — and trains the state's oncologists through web-based molecular tumor boards to interpret and act on those results. In addition, he has and continues to practice as a hematologist/oncologist at Northern Light Cancer Institute since 2010, treating patients with cancer while building the research infrastructure to transform their care.

Rueter is now leading an effort to scale MCGI's flagship program to community oncology practices around the country and building an AI-assisted decision support platform for JAX's Genomic Tumor Board, designed to help oncologists identify the best evidence-supported treatment options for patients with complex genomic profiles.

After graduating from medical school at the Charité in Berlin, Germany, Rueter completed his residency in internal medicine at Tulane University and fellowship training in hematology/oncology at the University of Pennsylvania.

RECEPTION AND POSTER FAIR

Mix, mingle and discover.

Continue the conversation
over refreshments and
explore highlights from JAX
research through a curated
selection of posters.

RARE DISEASE

DANA LAYO-CARRIS, Ph.D.,

SENIOR STUDY DIRECTOR,
RARE DISEASE TRANSLATIONAL CENTER
AT THE JACKSON LABORATORY

More than 10,000 rare diseases exist, but 95% have no approved treatment — even though 80% are caused by a known genetic change. The Rare Disease Translation Center (RDTC) closes that gap by turning genetic discoveries into real treatments. Working across 75+ genetic diseases, RDTC uses a “platform” approach: a repeatable pipeline from identifying a disease-causing gene, through building mouse and iPSC models and testing candidate therapies, to preparing treatments for clinical trials — making rare disease treatment faster and cheaper. Recent successes include base and prime gene-editing techniques that improved symptoms in mouse models of Alternating Hemiplegia of Childhood, Dravet Syndrome, and Zellweger Spectrum Disorder.

AGING

RON KORSTANJE, Ph.D.,

PROFESSOR, EVNIN FAMILY CHAIR

Cancer is far more common after age 65, yet most research relies on young, genetically identical mice. In response, JAX created the Genetic and Aging Influences on Neoplastic Susceptibility (GAINS) project to study tumor development in older, genetically diverse mice. Early findings show promise in predicting how age-related cancers develop and respond to treatments.

CANCER

JAMES MILLER, Ph.D.,

ASSOCIATE RESEARCH SCIENTIST,
TROWBRIDGE LAB

Clonal hematopoiesis is an age-related condition in which certain blood stem cells acquire genetic mutations that allow them to multiply more than normal cells, and it has been linked to an increased risk of heart disease, stroke, osteoporosis and some blood cancers. In this study, researchers found that a common mutation called DNMT3A changes the bone marrow environment, altering the structural support system around blood stem cells in ways that appear to favor the growth of the mutated cells. These findings suggest that future treatments could potentially target the bone marrow environment itself to slow the expansion of harmful mutated cells and reduce the risk of diseases associated with aging.

NEUROLOGICAL DISORDERS

ELIZABETH PIZZI

PREDOCTORAL ASSOCIATE, HOWELL LAB

The strongest correlate of cognitive decline within Alzheimer’s disease is the loss of healthy synaptic connection between neurons. One potential driving mechanism is through the complement system — an immunological process which becomes aberrantly activated resulting in the removal of synapses. This project aims to uncover insight into the molecular and cellular players driving these processes in Alzheimer’s disease.

Thank you to our
SPONSORS

DISCOVERY DRIVER SPONSOR



VISIONARY SPONSOR



You matter more.®

Member FDIC

Help shape the future of human health

Your support enables The Jackson Laboratory to accelerate new discoveries in our ongoing mission to find genomic solutions for human disease.

Philanthropy powers JAX's research initiatives, educational programs for up-and-coming scientists, recruitment and retention of the brightest minds and much more.

To make your gift now, scan the QR code below or mail it to:

The Jackson Laboratory
Advancement Office
PO Box 411423
Boston, MA 02241-1423



Visit us at www.jax.org/give for other ways to make your gift, including gifts by phone, stock gifts, and planned gifts. We are grateful for your support!



**The Jackson
Laboratory**

*Leading the search
for tomorrow's cures*